{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:12:24Z","timestamp":1792714344347,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejca.2025.115301","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:05:05Z","timestamp":1739318705000},"page":"115301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study"],"prefix":"10.1016","volume":"219","author":[{"given":"M.","family":"Wislez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mascaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.D.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ricordel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Swalduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Veillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gounant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rousseau-Bussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Madroszyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ravoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-C.","family":"Metivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fournel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Missy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Guisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2025.115301_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21037\/tcr-23-1477","article-title":"CodeBreak 200: study limitations, and future directions","volume":"13","author":"Alharbi","year":"2024","journal-title":"Transl Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115301_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"23","key":"10.1016\/j.ejca.2025.115301_bib3","first-page":"00572","article-title":"Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer","volume":"S1556-0864","author":"Chour","year":"2023","journal-title":"J Thorac Oncol: Publ Int Assoc Study Lung Cancer, mai"},{"key":"10.1016\/j.ejca.2025.115301_bib4","unstructured":"\u00ab\u2009Demande d\u2019autorisation d\u2019acc\u00e8s pr\u00e9coce \u00bb. s. d. ANSM. Consult\u00e9 le 13 septembre 2024. https:\/\/ansm.sante.fr\/vos-demarches\/industriel\/demande-dautorisation-dacces-precoce."},{"key":"10.1016\/j.ejca.2025.115301_bib5","article-title":"Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: a brief report","volume":"36","author":"Desai","year":"2023","journal-title":"Cancer Treat Res Commun"},{"issue":"18","key":"10.1016\/j.ejca.2025.115301_bib6","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1200\/JCO.22.02524","article-title":"Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100","volume":"41","author":"Dy","year":"2023","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"issue":"mars","key":"10.1016\/j.ejca.2025.115301_bib7","article-title":"Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis","volume":"102","author":"Ernst","year":"2024","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.ejca.2025.115301_bib8","article-title":"KRAS as a prognostic and predictive marker in metastatic non-small cell lung carcinoma: a systematic review","volume":"16","author":"Fatima","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.ejca.2025.115301_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0169-5002(98)00020-8","article-title":"Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?","volume":"20","author":"Kelly","year":"1998","journal-title":"Lung Cancer"},{"issue":"10378","key":"10.1016\/j.ejca.2025.115301_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"Langen","year":"2023","journal-title":"Lancet (Lond, Engl)"},{"issue":"9, ement","key":"10.1016\/j.ejca.2025.115301_bib11","first-page":"S10","article-title":"OA03.06 CodeBreaK 100\/101: First Report of Safety\/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC","volume":"17","author":"Li","year":"2022","journal-title":"J Thorac Oncol, Abstr 2022 World Conf Lung Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2025.115301_bib12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.ctrv.2014.05.007","article-title":"Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature","volume":"40","author":"Lombardi","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.ejca.2025.115301_bib13","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd.2016.139","article-title":"Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design","volume":"15","author":"Ostrem","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2025.115301_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107444","article-title":"Sotorasib in KRASp.G12C mutated advanced NSCLC: real-world data from the italian expanded access program","author":"Passiglia","year":"2024","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2025.115301_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37120","article-title":"Association of performance status with survival in patients with advanced non\u2013small cell lung cancer treated with pembrolizumab monotherapy","volume":"4","author":"Sehgal","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ejca.2025.115301_bib16","first-page":"17","article-title":"Cancer Statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: A Cancer J Clin"},{"issue":"25","key":"10.1016\/j.ejca.2025.115301_bib17","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115301_bib18","unstructured":"Staff. 2021. \u00ab Further Analyses Expand Upon Duration of Benefit With Sotorasib in KRAS G12C+ NSCLC \u00bb, Targeted Therapies in Oncology, 10 (octobre). https:\/\/www.targetedonc.com\/view\/further-analyses-expand-upon-duration-of-benefit-with-sotorasib-in-kras-g12c-nsclc."},{"key":"10.1016\/j.ejca.2025.115301_bib19","unstructured":"\u2014\u2014\u2014. 2024. \u00ab\u2009Experts Examine the Need for Targeted Therapy Options for KRAS G12C\u2013Mutated NSCLC \u00bb\u2009, Oncology, 38 (f\u00e9vrier):15\u201117."},{"key":"10.1016\/j.ejca.2025.115301_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113911","article-title":"Sotorasib in KRAS G12C -mutated non-small cell lung cancer: a multicenter real-world experience from the compassionate use program in Germany","author":"Stratmann","year":"2024","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2025.115301_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103473","article-title":"Clinical Characteristic and Survival Outcomes of Patients with Advanced NSCLC According to KRAS Mutational Status in the French Real-Life ESME Cohort","volume":"9","author":"Thomas","year":"2024","journal-title":"ESMO Open"},{"issue":"juin","key":"10.1016\/j.ejca.2025.115301_bib22","article-title":"Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer","volume":"7","author":"Thummalapalli","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115301_bib23","doi-asserted-by":"crossref","DOI":"10.21037\/tcr-23-2232","article-title":"The analysis of the efficacy and safety of stereotactic body radiotherapy with sequential immune checkpoint inhibitors in the management of oligoprogressive advanced non-small cell lung cancer","volume":"13","author":"Ying","year":"2024","journal-title":"Transl Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T09:06:27Z","timestamp":1741597587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925000826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":23,"alternative-id":["S0959804925000826"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115301","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115301"}}